Sherlock Biosciences, a biotechnology company, agreed to acquire Sense Biodetection, a global molecular diagnostics innovator. Financial terms were not disclosed. "This is a powerful combination of proprietary and leading technologies and will allow Sense to realize our vision of delivering the future of diagnostic testing to transform healthcare. Joining Sherlock with their novel CRISPR technology was an excellent opportunity and we look forward to advancing our platform to meet the need for testing wherever and whenever it is needed," Timothy Still, Sense Biodetection CEO.